Insider Cluster (2 insiders) ·Filed Aug 24, 2026

ABCL

AbCellera Biologics Inc.
MIXED
Impact 5/10
Horizonweeks Processed1mo ago
Insider cluster: 2 insiders, $681K total
Actionable Insight ◆ Mixed

Director buying after a dilutive offering is a modestly bullish signal, but the small dollar amount relative to market cap limits conviction. Monitor for additional insider purchases or a catalyst event (e.g., ABCL635 data update) that could confirm the bullish read. The cross-filing context of the $200M offering remains the dominant near-term bearish factor.

DirectionMixed
Confidencemedium
Horizonweeks
Latest settled — T+20d
ABCL ▲ +19.23% at T+20d
NEUTRAL call ✓ call won +19.23% · α vs SPY +17.91% · entry $10.61 → $12.65
Next anchor: T+60d in 6w
Latest observation: T+26 +8.06% FF3 residual α
Entry anchored
Aug 21, 07:59 PM ET
via 1-min bar
T+1d
+17.81%
call +17.81% · α +17.49%
$12.50
settled 6w ago
T+5d
+8.20%
call +8.20% · α +7.73%
$11.48
settled 5w ago
T+20d
+19.23%
call +19.23% · α +17.91%
$12.65
settled 11d ago
T+60d
—
call — · α —
—
in 6w

Price Chart

Loading chart...

Executive Summary

Two directors at AbCellera made open-market purchases totaling $681K, with the largest buy ($570K) occurring 13 days after a $200M dilutive offering. The insider buying follows a 93% bullish analyst consensus and positive Phase 2 data for ABCL635, but the capital raise creates a conflicting signal. Director purchases after a dilutive offering are unusual and may indicate confidence in the pipeline, though the cluster size is modest relative to the $3.3B market cap.

Key Financial Metrics

Direction
buying
Total Value
$681.0K
Insiders
2

Key Facts

  • Two directors purchased $681K in open-market transactions over a 7-day window
  • Largest buy: Director Michael R. Hayden purchased 53,613 shares at $10.64 for $570K
  • Purchases follow a $200M dilutive offering (424B5) filed 13 days prior on August 11, 2026
  • Total insider buying represents ~0.02% of the $3.3B market cap
  • 93% of analysts rate the stock as Buy or Strong Buy

Financial Impact

$681K in insider purchases, representing 0.02% of market cap

insider ownershipdilution

Risk Factors

  • Insider buying is small relative to market cap and may not signal broad confidence
  • The $200M dilutive offering overhangs the stock and could pressure near-term price
  • No C-suite participation in the buying cluster reduces signal strength

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ABCL-1787645044366
12 reports for ABCL
Performance horizon
88% Hit rate 7 of 8 directional calls best @ T+20▲ +127.09%Jul 29, 2026
Filters
Rows
Reports for ABCL — sortable, filterable
TypeNow
Aug 24, 2026
5w ago
Insider Cluster
MIXED ★ 5/10
$10.61 $12.65▲ +19.23%▲ +17.91%$13.74 (+29.50%)
Aug 18, 2026
6w ago
Insider Cluster
BULLISH ★ 5/10
$11.12 $11.67▲ +4.95%▲ +6.69%$13.74 (+23.56%)
Aug 15, 2026
6w ago
Institutional Cluster
BEARISH ★ 6/10
$11.20 $11.41▼ −1.88%▼ −3.85%$13.74 (−22.68%)
Aug 11, 2026
7w ago
424B5
BEARISH ★ 7/10
$10.36 $10.46▼ −1.01%▼ −2.91%$13.74 (−32.69%)
Aug 10, 2026
7w ago
8-K
BULLISH ★ 7/10
$9.34 $11.44▲ +22.48%▲ +23.40%$13.74 (+47.11%)
Jul 29, 2026
9w ago
8-K
BULLISH ★ 6/10
$5.39 $12.24▲ +127.09%▲ +122.07%$13.74 (+154.92%)
Jul 6, 2026
12w ago
3
NEUTRAL ★ 1/10
$7.69 $5.83▼ −24.19%▼ −25.52%$13.74 (+78.67%)
Jul 6, 2026
12w ago
8-K
NEUTRAL ★ 2/10
$7.87 $5.71▼ −27.45%▼ −26.88%$13.74 (+74.59%)
Jun 5, 2026
17w ago
8-K
NEUTRAL ★ 2/10
$5.62 $7.87▲ +40.04%▲ +38.17%$13.74 (+144.48%)
May 11, 2026
20w ago
8-K
BULLISH ★ 7/10
$4.95 $5.09▲ +2.83%▲ +4.56%$13.74 (+177.58%)
Showing 10 of 12

US Market Status

Market Closed — Opens Mon (37h 48m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Aug 25, 2026